Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00525512 · ClinicalTrials.gov registry record · Phase 4
Tiotropium In Exercise
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 519
- Enrollment target
NCT00525512 is a Phase 4 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 519 participants.
The verdict
NCT00525512, a Phase 4 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 519 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the effects on exercise duration of 96 weeks treatment with 18 mcg tiotropium (Spiriva HandiHaler) daily as compared to placebo, in patients with COPD.
Interventions
- DRUG Placebo
- DRUG tiotropium 18 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 519 participants |
| Start Date | 2007-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00525512
The ClinicalTrials.gov registry entry for NCT00525512 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 519 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00525512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00525512 about?
NCT00525512 is a clinical study titled "Tiotropium In Exercise". The objective of this study is to evaluate the effects on exercise duration of 96 weeks treatment with 18 mcg tiotropium (Spiriva HandiHaler) daily as compared to placebo, in patients with COPD.
What is the current status of trial NCT00525512?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 519 participants. The study started on 2007-08.
What interventions are being tested in trial NCT00525512?
The interventions under investigation include: Placebo (DRUG), tiotropium 18 mcg (DRUG).
Who is sponsoring clinical trial NCT00525512?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.